PROKALSITONIN COVİD-19’ DA KULLANILABİLECEK BİR BİYOMARKER MI?

Serpil Mızrakçı; Havva Yasemin Çinpolat

Review

PROKALSITONIN COVİD-19’ DA KULLANILABİLECEK BİR BİYOMARKER MI?

Year 2022, Volume: 4 Issue: 2, 148 - 155, 30.06.2022

Serpil Mızrakçı , Havva Yasemin Çinpolat

Abstract

COVID-19 pademisi yaklaşık iki yıldır tüm dünyada etkisini göstermektedir. Hastalığın gerek seyri, gerek tedavisi, gerekse de önlenmesi ile ilgili çalışmalar hız kesmeden devam etmektedir. Ancak pandemi henüz tam olarak kontrol altına alınamamıştır. Hastalığa bağlı ölümler ve sekelller devam etmektedir. Hastalığın seyrini tahmin etmede kullanılabilceği tahmin edilen biyomarker çalışmaları da devam etmektedir. Prokalsitonin de bu biyomarkerlardan biridir. Bu belirteç öncesinde sepsis ve solunum yolu enfeksiyonlarında kullanılan bir markerdır. Bu çalışmada, COVID-19’da prokalsitonin etkisini araştıran literatürün gözden geçirilmesi amaçlandı.

Keywords

COVID-19, prokalsitonin, SARS-COV 2

Supporting Institution

yok

Project Number

yok

References

1. Müller B, White JC, Nylén ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab. 2001;86(1):396-404.
2. Wiedermann FJ, Kaneider N, Egger P, Tiefenthaler W, Wiedermann CJ, Lindner KH, Schobersberger W. Migration of human monocytes in response to procalcitonin. Crit Care Med. 2002;30(5):1112-1117.
3. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993;341(8844):515-518.
4. Alkan Çeviker S, Dindar Demiray E. K. SARS-CoV-2 (COVİD 19) Enfeksiyonu Ayırıcı Tanı Açısından Diğer Solunumsal Virüsler. Biotech&Strategic Health Res. 2020; 4: 45-49.
5. Hamade B, Huang DT. Procalcitonin: Where Are We Now? Crit Care Clin. 2020;36(1):23-40.
6. Liu D, Su L, Han G, Yan P, Xie L. Prognostic Value of Procalcitonin in Adult Patients with Sepsis: A Systematic Review and Meta-Analysis. PLoS One. 2015;10(6):e0129450.
7. Kamat IS, Ramachandran V, Eswaran H, Guffey D, Musher DM. Procalcitonin to Distinguish Viral From Bacterial Pneumonia: A Systematic Review and Meta-analysis. Clin Infect Dis. 2020;70(3):538-542.
8. https://www.statista.com/statistics/1104709/coronavirus-deaths-worldwide-per-million-inhabitants/. Erişim tarihi: 10 Mart 2022.
9. Alkan S, Akça A, Şener A, Doğan E, Gönlügür U, Şimşek T, et al. Evaluation of the hospitalized coronavirus disease 2019 patients in first 3 months of the pandemic. Turk Thorac J. 2022;23(1):52-57.
10. Yıldız E, Alkan S, Tokur ME, Balcı C. COVID-19’da Oksijen Tedavisi. İstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi. 2021; (14): 376-388.
11. Alkan S, Önder T, Şener A, Doğan E, Gönlügür U, Şimşek T, et al. Comparisons of treatment protocols for SARS-COV-2 in early pandemic: Single center experience in Turkey. J Contemp Med. 2022; 12(2): 1-1.
12. Yildiz E, Tokur ME, Özlem B, Arik Ö, Baldi C. Evaluation of the efficacy of immune plasma treatment in COVID-19 infected intensive care unit patients. Iberoam J Med. 2022;4(1):37-44.
13. Evlice O, Kuş F, Bektaş M. Persistent Symptoms After Discharge of COVID-19 Patients. Infect Dis Clin Microbiol. 2021; 1: 22-29.
14. Küçük U, Alkan Çeviker S, Şener A. Relationship between in-hospital mortality and inflammation markers in COVID-19 patients with the diagnosis of coronary artery disease. J Contemp Med. 2021; 11(3): 267-271.
15. Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020;57(6):389-399.
16. Evlice O, Kuş F, Bektaş M. Predictive relevance of different clinical and laboratory findings for higher mortality in patients with COVID-19 in a single center cohort: Neutrophil Lymphocyte Ratio, high CRP, GGT and creatinine levels are associated with high mortality. Journal of Istanbul Faculty of Medicine. 2022; 1-2.
17. Hu R, Han C, Pei S, Yin M, Chen X. Procalcitonin levels in COVID-19 patients. Int J Antimicrob Agents. 2020;56(2):106051.
18. Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chim Acta. 2020; 505: 190-191.
19. Shen Y, Cheng C, Zheng X, et al. Elevated Procalcitonin Is Positively Associated with the Severity of COVID-19: A Meta-Analysis Based on 10 Cohort Studies. Medicina (Kaunas). 2021;57(6):594.
20. Huang I, Pranata R, Lim MA, Oehadian A, Alisjahbana B. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther Adv Respir Dis. 2020;14:1753466620937175.
21. Vazzana N, Dipaola F, Ognibene S. Procalcitonin and secondary bacterial infections in COVID-19: association with disease severity and outcomes. Acta Clin Belg. 2022;77(2):268-272.
22. Wolfisberg S, Gregoriano C, Schuetz P. Procalcitonin for individualizing antibiotic treatment: an update with a focus on COVID-19. Crit Rev Clin Lab Sci. 2022;59(1):54-65.
23. Heer RS, Mandal AK, Kho J, et al. Elevated procalcitonin concentrations in severe Covid-19 may not reflect bacterial co-infection. Ann Clin Biochem. 2021;58(5):520-527.
24. Adams B, Beaney A. Interpreting serum procalcitonin in COVID-19 patients undergoing renal replacement therapy. J Glob Antimicrob Resist. 2021; 27: 324-325.
25. Güçlü Kayta SF, Alkan Çeviker S, Önder T, Akça A, Yüksel C, Vurucu S, et al. A case of COVID-19 pneumonia in an immunosuppressed patient with late-onset of respiratory symptoms. D J Med Sci. 2021;7(3):288-292.
26. Mutlu P, Mirici A. How did COPD pose a lower risk than expected for COVID19?. Troia Medical Journal. 2022; 3(1): 10-14.
27. Dindar Demiray EK, Yılmaz M, Alıravcı ID, Alkan S. COVID-19-Akut Pankreatit İlişkisinin İncelenmesi. İstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi. 2021; (13): 130-143.
28. Gökçe ON. Elevation of pancreatic enzymes during SARS-CoV-2 infection. D J Med Sci. 2021;7(3):334-338.
29. Durgun C. The relationship between SARS-CoV-2 infection and cholangiopathy. D J Med Sci. 2021;7(3):339-340.
30. Cancan Gürsul N, Alkan S, Vurucu S. İshal ve Deri Bulguları ile Başvuran Bir Atipik COVID-19 Olgusu. Black Sea Journal of Health Science. 2022; 19-20.
31. Duygu A, Küçük U, Arslan M. Akut miyokard infarktüsü ile başvuran bir COVID-19 hastasına yaklaşım. Troia Medical Journal. 2021; 2(1): 40-43.
32. Dindar Demiray EK, Sim Yıldırım S, Karaduman A. COVID-19 pnömonisi subakut tiroidite sebep olur mu?. Troia Medical Journal. 2021; 2(2): 47-48.
33. Alkan Çeviker S, Güçlü Kayta SB, Şener A. Unutulmaması gereken hastalık: COVID 19 pnömonisine eşlik eden bir subakut tiroidit. Troia Medical Journal. 2021; 2(1): 1-2.
34. Alıravcı I, Alkan Çeviker S. COVID-19 Karaciğer Tutulumu ve Altta Yatan Karaciğer Hastalığı Olanlarda Hastalık Seyrinin İrdelenmesi: Derleme. J Biotechinol & Strategic Health Res. 2020; 4(3): 206-211.
35. Küçük U, Kırılmaz B. COVID-19 pandemisinin kardiyovasküler sistem üzerine etkileri. Troia Medical Journal. 2021; 2(1): 33-36.
36. Alkan Çeviker S, Şener A, Yüksel C, Önder T, Akça A, Vurucu S, et al. Angioedema and acute urticaria in a patient with COVID 19 pneumonia: Favipiravir side effect or COVID-19 cutaneous manifestation. Journal of Emergency Medicine Case Reports. 2021; 12(2): 65-67.
37. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(5):426-435.
38. Yağlı N, Ok G, Tok D, Taneli F, Ulman C, Erbüyün K. Sepsis Tanısında Prokalsitonin Belirleyiciliği.Yoğun Bakım Dergisi. 2010;9(1):42-50.

IS PROCALCITONIN A BIOMARKER THAT CAN BE USED IN COVID-19?

Year 2022, Volume: 4 Issue: 2, 148 - 155, 30.06.2022

Serpil Mızrakçı , Havva Yasemin Çinpolat

Abstract

The COVID-19 pandemic has been affecting the whole world for about two years. Studies on the course, treatment and prevention of the disease continue without slowing down. However, the pandemic has not yet been fully brought under control. Disease-related deaths and sequelae continue. Biomarker studies, which are used to predict the course of the disease, are also ongoing. Procalcitonin is one of these biomarkers. This marker was previously used in sepsis and respiratory tract infections. In this study, it was aimed to review the literature investigating the effect of procalcitonin in COVID-19.

Keywords

COVID-19, procalcitonin, SARS-COV 2

Project Number

yok

References

1. Müller B, White JC, Nylén ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab. 2001;86(1):396-404.
2. Wiedermann FJ, Kaneider N, Egger P, Tiefenthaler W, Wiedermann CJ, Lindner KH, Schobersberger W. Migration of human monocytes in response to procalcitonin. Crit Care Med. 2002;30(5):1112-1117.
3. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993;341(8844):515-518.
4. Alkan Çeviker S, Dindar Demiray E. K. SARS-CoV-2 (COVİD 19) Enfeksiyonu Ayırıcı Tanı Açısından Diğer Solunumsal Virüsler. Biotech&Strategic Health Res. 2020; 4: 45-49.
5. Hamade B, Huang DT. Procalcitonin: Where Are We Now? Crit Care Clin. 2020;36(1):23-40.
6. Liu D, Su L, Han G, Yan P, Xie L. Prognostic Value of Procalcitonin in Adult Patients with Sepsis: A Systematic Review and Meta-Analysis. PLoS One. 2015;10(6):e0129450.
7. Kamat IS, Ramachandran V, Eswaran H, Guffey D, Musher DM. Procalcitonin to Distinguish Viral From Bacterial Pneumonia: A Systematic Review and Meta-analysis. Clin Infect Dis. 2020;70(3):538-542.
8. https://www.statista.com/statistics/1104709/coronavirus-deaths-worldwide-per-million-inhabitants/. Erişim tarihi: 10 Mart 2022.
9. Alkan S, Akça A, Şener A, Doğan E, Gönlügür U, Şimşek T, et al. Evaluation of the hospitalized coronavirus disease 2019 patients in first 3 months of the pandemic. Turk Thorac J. 2022;23(1):52-57.
10. Yıldız E, Alkan S, Tokur ME, Balcı C. COVID-19’da Oksijen Tedavisi. İstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi. 2021; (14): 376-388.
11. Alkan S, Önder T, Şener A, Doğan E, Gönlügür U, Şimşek T, et al. Comparisons of treatment protocols for SARS-COV-2 in early pandemic: Single center experience in Turkey. J Contemp Med. 2022; 12(2): 1-1.
12. Yildiz E, Tokur ME, Özlem B, Arik Ö, Baldi C. Evaluation of the efficacy of immune plasma treatment in COVID-19 infected intensive care unit patients. Iberoam J Med. 2022;4(1):37-44.
13. Evlice O, Kuş F, Bektaş M. Persistent Symptoms After Discharge of COVID-19 Patients. Infect Dis Clin Microbiol. 2021; 1: 22-29.
14. Küçük U, Alkan Çeviker S, Şener A. Relationship between in-hospital mortality and inflammation markers in COVID-19 patients with the diagnosis of coronary artery disease. J Contemp Med. 2021; 11(3): 267-271.
15. Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020;57(6):389-399.
16. Evlice O, Kuş F, Bektaş M. Predictive relevance of different clinical and laboratory findings for higher mortality in patients with COVID-19 in a single center cohort: Neutrophil Lymphocyte Ratio, high CRP, GGT and creatinine levels are associated with high mortality. Journal of Istanbul Faculty of Medicine. 2022; 1-2.
17. Hu R, Han C, Pei S, Yin M, Chen X. Procalcitonin levels in COVID-19 patients. Int J Antimicrob Agents. 2020;56(2):106051.
18. Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chim Acta. 2020; 505: 190-191.
19. Shen Y, Cheng C, Zheng X, et al. Elevated Procalcitonin Is Positively Associated with the Severity of COVID-19: A Meta-Analysis Based on 10 Cohort Studies. Medicina (Kaunas). 2021;57(6):594.
20. Huang I, Pranata R, Lim MA, Oehadian A, Alisjahbana B. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther Adv Respir Dis. 2020;14:1753466620937175.
21. Vazzana N, Dipaola F, Ognibene S. Procalcitonin and secondary bacterial infections in COVID-19: association with disease severity and outcomes. Acta Clin Belg. 2022;77(2):268-272.
22. Wolfisberg S, Gregoriano C, Schuetz P. Procalcitonin for individualizing antibiotic treatment: an update with a focus on COVID-19. Crit Rev Clin Lab Sci. 2022;59(1):54-65.
23. Heer RS, Mandal AK, Kho J, et al. Elevated procalcitonin concentrations in severe Covid-19 may not reflect bacterial co-infection. Ann Clin Biochem. 2021;58(5):520-527.
24. Adams B, Beaney A. Interpreting serum procalcitonin in COVID-19 patients undergoing renal replacement therapy. J Glob Antimicrob Resist. 2021; 27: 324-325.
25. Güçlü Kayta SF, Alkan Çeviker S, Önder T, Akça A, Yüksel C, Vurucu S, et al. A case of COVID-19 pneumonia in an immunosuppressed patient with late-onset of respiratory symptoms. D J Med Sci. 2021;7(3):288-292.
26. Mutlu P, Mirici A. How did COPD pose a lower risk than expected for COVID19?. Troia Medical Journal. 2022; 3(1): 10-14.
27. Dindar Demiray EK, Yılmaz M, Alıravcı ID, Alkan S. COVID-19-Akut Pankreatit İlişkisinin İncelenmesi. İstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi. 2021; (13): 130-143.
28. Gökçe ON. Elevation of pancreatic enzymes during SARS-CoV-2 infection. D J Med Sci. 2021;7(3):334-338.
29. Durgun C. The relationship between SARS-CoV-2 infection and cholangiopathy. D J Med Sci. 2021;7(3):339-340.
30. Cancan Gürsul N, Alkan S, Vurucu S. İshal ve Deri Bulguları ile Başvuran Bir Atipik COVID-19 Olgusu. Black Sea Journal of Health Science. 2022; 19-20.
31. Duygu A, Küçük U, Arslan M. Akut miyokard infarktüsü ile başvuran bir COVID-19 hastasına yaklaşım. Troia Medical Journal. 2021; 2(1): 40-43.
32. Dindar Demiray EK, Sim Yıldırım S, Karaduman A. COVID-19 pnömonisi subakut tiroidite sebep olur mu?. Troia Medical Journal. 2021; 2(2): 47-48.
33. Alkan Çeviker S, Güçlü Kayta SB, Şener A. Unutulmaması gereken hastalık: COVID 19 pnömonisine eşlik eden bir subakut tiroidit. Troia Medical Journal. 2021; 2(1): 1-2.
34. Alıravcı I, Alkan Çeviker S. COVID-19 Karaciğer Tutulumu ve Altta Yatan Karaciğer Hastalığı Olanlarda Hastalık Seyrinin İrdelenmesi: Derleme. J Biotechinol & Strategic Health Res. 2020; 4(3): 206-211.
35. Küçük U, Kırılmaz B. COVID-19 pandemisinin kardiyovasküler sistem üzerine etkileri. Troia Medical Journal. 2021; 2(1): 33-36.
36. Alkan Çeviker S, Şener A, Yüksel C, Önder T, Akça A, Vurucu S, et al. Angioedema and acute urticaria in a patient with COVID 19 pneumonia: Favipiravir side effect or COVID-19 cutaneous manifestation. Journal of Emergency Medicine Case Reports. 2021; 12(2): 65-67.
37. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(5):426-435.
38. Yağlı N, Ok G, Tok D, Taneli F, Ulman C, Erbüyün K. Sepsis Tanısında Prokalsitonin Belirleyiciliği.Yoğun Bakım Dergisi. 2010;9(1):42-50.

There are 38 citations in total.

Details

Primary Language	Turkish
Subjects	Clinical Sciences
Journal Section	Basic Sciences
Authors	Serpil Mızrakçı 0000-0002-7331-5877 Havva Yasemin Çinpolat 0000-0002-7161-2907
Project Number	yok
Publication Date	June 30, 2022
Submission Date	March 12, 2022
Published in Issue	Year 2022 Volume: 4 Issue: 2

Cite

Vancouver	Mızrakçı S, Çinpolat HY. PROKALSITONIN COVİD-19’ DA KULLANILABİLECEK BİR BİYOMARKER MI?. Dent & Med J - R. 2022;4(2):148-55.

Download Cover Image

Article Files

Full Text

"The truest guide for everything in the world, for civilization, for life, for success, is science. Seeking a guide outside of science and science is heedlessness, ignorance, and deviating from the right path. It is only necessary to understand the development of science and science in every minute we live and to follow the progress in time. To attempt to apply the rules of science and science a thousand, two thousand, and thousands of years ago, today, after so many thousand years, is, of course, not to be in science and science."

M. Kemal ATATÜRK